Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1 2

Status

Recruiting 10Unknown 7Not yet recruiting 5Terminated 4Completed 3Active not recruiting 3Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1

Conditions

Retinoblastoma 1Retinal Neoplasms 1Oropharyngeal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Platinum Compounds × Clear all
NCT06234748 2026-05-18

ARTHOUSE

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
19 enrolled
Head & Neck

Oropharyngeal Neoplasms

NCT02866136 2025-11-24

RETINO2011

Institut Curie

Phase 2 Active not recruiting
133 enrolled
Other solid neoplasm

Retinoblastoma, Retinal Neoplasms

NCT04379739 2023-12-06

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Active not recruiting
89 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡